Is evantumumab a targeted or immune drug?

Amivantamab (amivantamab-vmjw) is a humanized bispecific antibody targeting EGFR (epidermal growth factor receptor) and MET (mesothelin receptor) and has immune cell guidance activity. The drug plays its role in tumor treatment by simultaneously targeting and inhibiting the activity of two types of proteins: EGFR and MET.

Specifically, evantumumab can directly block the EGFR outside cells and prevent tumor growth. In addition, it works with the body's immune system to use EGFR to identify and destroy cancer cells. The mechanism of action of this drug involves multiple Fc-independent and Fc-dependent mechanisms of action on tumor cells related to EGFR and MET, resulting in anti-tumor activity.

Evantumumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations that have progressed after platinum-based chemotherapy. These patients often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies, so evantumumab provides them with a new treatment option. In addition, since the drug is a bispecific antibody targeting EGFR resistance mutations, MET mutations and amplifications, it can also be used to treat other types of cancer, which requires further research and clinical trials to confirm.

In general, evantumumab is a targeted drug that can simultaneously inhibit the activities of EGFR and MET, thereby exerting anti-tumor effects. The drug provides a new treatment option for NSCLC patients with EGFR exon 20 insertion mutations and is expected to be used to treat other types of cancer in the future. However, as a drug, the use of evantuzumab needs to follow the advice and guidance of your doctor to ensure its safety and effectiveness.